Galecto, Inc. (GLTO)

Market Cap	16.41M
Revenue (ttm)	n/a
Net Income (ttm)	-45.94M
Shares Out	27.11M
EPS (ttm)	-1.77
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	26,697
Open	0.600
Previous Close	0.600
Day's Range	0.600 - 0.620
52-Week Range	0.500 - 3.700
Beta	1.01
Analysts	Buy
Price Target	9.00 (+1,387.6%)
Earnings Date	Nov 6, 2023

About GLTO

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled small molecule inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; GB2064, a selective oral small mo...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 29, 2020
• Employees: 45
• Stock Exchange: NASDAQ
• Ticker Symbol: GLTO

Analyst Forecast

According to 5 analysts, the average rating for GLTO stock is "Buy." The 12-month stock price forecast is $9.0, which is an increase of 1,387.60% from the latest price.

Price Target

$9.0

(1,387.60% upside)

Analyst Consensus: Buy